Cognition Therapeutics (NASDAQ:CGTX) Price Target Lowered to $8.00 at Chardan Capital

Cognition Therapeutics (NASDAQ:CGTX) had its price target reduced by Chardan Capital from $11.00 to $8.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Other research analysts have also recently issued reports about the company. Brookline Capital Management upgraded Cognition Therapeutics to a “strong-buy” rating in a report on Monday, January 27th. HC Wainwright lifted their target price on Cognition Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Thursday, December 19th. Finally, B. Riley raised Cognition Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $1.00 to $1.50 in a research report on Thursday, December 19th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $7.70.

Cognition Therapeutics Stock Down 5.2 %

Cognition Therapeutics stock opened at $0.43 on Friday. The company has a fifty day simple moving average of $0.59 and a 200-day simple moving average of $0.55. The firm has a market capitalization of $17.73 million, a price-to-earnings ratio of -0.44 and a beta of 1.03. Cognition Therapeutics has a 52-week low of $0.34 and a 52-week high of $2.95.

Cognition Therapeutics (NASDAQ:CGTX) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.01). During the same quarter in the prior year, the firm earned ($0.27) EPS. On average, research analysts anticipate that Cognition Therapeutics will post -0.8 EPS for the current fiscal year.

Hedge Funds Weigh In On Cognition Therapeutics

Institutional investors have recently modified their holdings of the business. Virtu Financial LLC boosted its stake in shares of Cognition Therapeutics by 40.1% during the fourth quarter. Virtu Financial LLC now owns 80,180 shares of the company’s stock worth $56,000 after buying an additional 22,949 shares during the period. Geode Capital Management LLC raised its stake in Cognition Therapeutics by 8.9% during the 4th quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock valued at $247,000 after acquiring an additional 28,705 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Cognition Therapeutics during the 4th quarter worth approximately $26,000. Two Sigma Investments LP grew its stake in shares of Cognition Therapeutics by 372.2% in the 4th quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock valued at $38,000 after purchasing an additional 42,321 shares during the last quarter. Finally, Sigma Planning Corp increased its holdings in shares of Cognition Therapeutics by 211.6% in the fourth quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock valued at $431,000 after purchasing an additional 417,300 shares during the period. 43.35% of the stock is owned by institutional investors and hedge funds.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.